Apple Health App to Feature Quest Diagnostics Biomarker Testing
Yahoo Finance ·
Beginning later this year, users of the Apple Health app in the United States will gain the ability to seamlessly purchase and access tailored laboratory tests from Quest Diagnostics directly on their iPhone and iPad devices. Announced on September 9, 2026, by Secaucus, New Jersey-based Quest Diagnostics (NYSE: DGX), the integration introduces a comprehensive panel featuring over 50 biomarkers designed to evaluate cardiometabolic health and organ function. Priced at $119, customers can schedule their blood draws and biometric assessments at roughly 2,000 patient service centers nationwide. Results will be delivered directly into the Apple Health platform, backed by independent physician reviews and complimentary follow-up consultations. This initiative aims to bridge clinical and preventive health care for millions of Americans.
AI 시장 분석
Apple (AAPL) announced at its September event that, starting later this year, US Apple Health app users will be able to directly order over 50 biomarker tests from Quest Diagnostics (DGX) and view their results. Through this partnership, users can apply for customized preventive tests including cardiometabolic health and organ function for $119. This accelerates the convergence of healthcare and consumer technology, serving as an opportunity to expand the service ecosystems of related companies.
상승 영향
- Healthcare — Demand for preventive medicine and healthcare services will significantly increase with the introduction of direct ordering services for over 50 Quest Diagnostics biomarker tests via the Apple Health app.
DYAX 전담 분석
This integration is expected to bring direct revenue expansion for both companies through the influx of new customers and increased service usage. In particular, DGX can expect increased traffic to its approximately 2,000 patient service centers nationwide.
In the bull case, the service adoption rate will rise rapidly due to the surge in demand for preventive medicine, while in the bear case, utilization rates may be lower than expected due to privacy concerns or cost resistance. Future trends in in-app test orders and user growth should be closely monitored.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 51% · Bearish (Short) 49%
379 participants
Related News
- Michael Dell Surpasses Jeff Bezos to Become Third-Richest Person in the World
- iPhone Duo First Impressions: What It Really Feels Like to Use Apple's Folding Phone
- SailPoint, Inc. Q2 2027 Earnings Call Summary
- Salesforce Shares Slip 2% Amid Reports of Talks to Buy AI Startup Listen Labs for $2B
- Could Apple Stock Win as Intel Fades from the Mac Ecosystem?
- Jim Cramer Names Apple (AAPL) Ultimate Portfolio Quarterback
